Aurelia de Pauw

Corporate Officer/Principal presso TETRA BIO-PHARMA INC.

Health Technology

Consumer Services

Profilo

Aurelia de Pauw is currently the Director at TALLC Corp., Inc. and the Vice President-Clinical Programs & Medical Affairs at Tetra Bio-Pharma, Inc. She graduated from Faculté Universitaire des Sciences Agronomiques de Gembloux with a graduate degree in 2005 and received her doctorate degree from Université de Namur ASBL in the same year.

Posizioni attive di Aurelia de Pauw

Società	Posizione	Inizio
TETRA BIO-PHARMA INC.	Corporate Officer/Principal	01/10/2018
TALLC Corp., Inc. TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada.	Director/Board Member	-

Tutte le posizioni attive di Aurelia de Pauw

Formazione di Aurelia de Pauw

Faculté Universitaire des Sciences Agronomiques de Gembloux	Graduate Degree
Université de Namur ASBL	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Aurelia de Pauw

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
TETRA BIO-PHARMA INC.	Health Technology

Aziende private	1
TALLC Corp., Inc. TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada.	Health Technology